Sanofi is offering to publicly acknowledge that a competitor's flu vaccine is just as effective as its own — a move aimed at avoiding a hefty EU antitrust fine. The French pharma giant allegedly disparaged CSL Seqirus's "Fluad" vaccine to gain an edge over its own "Efluelda" in France and Germany. The EU is now seeking public feedback before deciding whether to accept Sanofi's commitments.
Sanofi is trying to sidestep a major EU antitrust fine by pledging to stop disparaging a rival flu vaccine. The European Commission opened an investigation into whether Sanofi unfairly badmouthed CSL Seqirus's "Fluad" vaccine — which competes directly with its own "Efluelda" — in France and Germany. Regulators say the behavior may have restricted competition in those markets.
To resolve the matter, Sanofi has offered to post statements on its German and French websites for two years, acknowledging that national immunization advisory bodies in both countries recommend both vaccines equally for elderly patients. The company also agreed to stop portraying Fluad negatively or misrepresenting scientific studies about the rival product. The commitments would remain in effect until March 2030, pending EU approval.
Key Takeaways:
Why it matters: This case highlights growing EU regulatory scrutiny over pharmaceutical companies using misleading tactics to undercut competitors — with real implications for fair vaccine market competition and, ultimately, patient access to equally effective options.
